Northern Data AG Opens First Own Data Center in Frankfurt
30.11.2020 10:58:00 EET | Business Wire | Press release
Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87) starts operating its first data center at its Frankfurt am Main location. From December 2020, the Frankfurt location will make up part of the Company's Distributed Computing Cluster, based on its mobile high-tech data centers. This will add to the Company's worldwide network of GPU clusters, including in the Netherlands, Scandinavia and Canada. Feasibility studies (Proof of Concept) are planned at the Frankfurt site in cooperation with research and industry.
Stefan Sickenberger, COO of Northern Data, explains: "High-Performance Computing has become an integral part of research and large parts of industry. Parallel processor systems and clusters are needed to process large volumes of data at high speed and with maximum stability. A key driver of success is lower energy consumption and high power efficiency. We are pleased to be working closely with our research partners on this project. We are particularly proud of our cooperation with the High-Performance Computing Architecture group at the Goethe University Frankfurt, which commands a great deal of expertise, especially in the area of Green IT".
Volker Lindenstruth, Professor of High-Performance Computing Architecture at Frankfurt Goethe University and member of the Board of Directors of the Frankfurt Institute for Advanced Studies (FIAS) comments: "We are delighted to be working with Northern Data. This project involves coupling the research supercomputers of Goethe University and the GSI Helmholtz Centre for Heavy Ion Research with Northern Data's own supercomputers, making the best use possible out of our combined capabilities and existing hardware. Peak loads can be intercepted, while particularly large jobs can be started with minimal delay. Example scientific applications include calculations and modelling in particle physics and relativistic astrophysics, environmental and atmospheric physics, as well as applications in life sciences, for example, precise and automated detection of cancer cells in tissue sections.
Aroosh Thillainathan, CEO of Northern Data, adds: "Above all, our concept of 'design-to-cost' is particularly important to this project. We not only manage the customer's data center and hardware but also the software, enabling us to optimize the data center operations to meet the customer's actual needs. In contrast to pure colocation providers, which have no influence on, for example, the load distribution of their customers and their software processing within the data center, we are able to regulate this with our management software. Among other things, we also control the cooling capacity very efficiently in terms of the required computing power, and this enables us to achieve excellent PUE values. Our customers save energy and achieve cost savings as a result. Together with our targeted selection of locations in northern regions, this allows us to offer our customers high-quality HPC solutions tailored to their needs, while remaining extremely cost-efficient at the same time.
About Northern Data:
Northern Data AG develops and operates global infrastructure solutions in the field of High-Performance Computing (HPC). With its customer-specific solutions, the company provides the infrastructure for various HPC applications in areas such as bitcoin mining, artificial intelligence, blockchain, big data analytics, IoT or rendering. The internationally active company is today a leading provider of HPC solutions worldwide. Northern Data offers its HPC solutions both in large, stationary data centers and in mobile high-tech data centers that can be set up at any location worldwide. The company combines self-developed software and hardware with intelligent concepts for a sustainable energy supply. The Northern Data group currently employs about 150 members of staff.
Disclaimer:
This press release does not constitute an offer to sell or a solicitation of an offer to purchase or subscribe for any securities of Northern Data AG, nor does it constitute a securities prospectus of Northern Data AG. The information contained in this press release is not intended to serve as a basis for financial, legal, tax or other business decisions. Investment or other decisions should not be based solely on this press release. As with all business and investment matters, please consult qualified professional advice.
|
Language: |
English |
|
Company: |
Northern Data AG
|
|
Phone: |
+49 69 34 87 52 25 |
|
E-mail: |
|
|
Internet: |
|
|
ISIN: |
DE000A0SMU87 |
|
WKN: |
A0SMU8 |
|
Listed: |
Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate Exchange |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201129005436/en/
Contact information
Northern Data AG
Dr. Hans Joachim Dürr
Head of Corporate Communications
e-mail: h.duerr@northerndata.de
Phone: +49 69 348 752 89
Investor Relations:
Sven Pauly
e-mail: ir@northerndata.de
Phone: +49 89 125 09 03 30
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
